BioAgilytix

Belkins
BioAgilytix is a leading bioanalytical contract research organization (CRO) that supports the development of novel therapeutic biologics and biosimilars. Located in Research Triangle Park, North Carolina, BioAgilytix specializes in large-molecule bioanalysis providing critical insight into the safety, efficacy, and mechanism of action of drug candidates throughout the clinical trial process.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

THROUGH CUTTING-EDGE MRNA AND AI TECHNOLOGY PLATFORMS, I-MAB EXPANDS ITS EMERGING PORTFOLIO OF NEXT-GENERATION NOVEL ONCOLOGY THERAPEUTICS

I-Mab | July 12, 2021

news image

I-Mab, a clinical-stage biopharmaceutical business dedicated to discovering, developing, and commercialization of novel biologics, announced today the signing of two new partnerships with Chinese emerging biotech firms to enhance its next-generation innovation pipeline. Collaborations with Immorna, an mRNA biotech company, and neoX Biotech, an AI-enabled R&D biotech company, provide I-Mab access to revolutionary technologies to search for new cancer treatments. I-Mab will crea...

Read More

GENSCRIPT RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR CPASS™ SARS-COV-2 NEUTRALIZATION ANTIBODY DETECTION KIT

GenScript | November 10, 2020

news image

GenScript USA Inc., the world's leading research reagent provider, announced today that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit. This is the first commercially available test to specifically detect neutralizing antibodies without the use of live virus. Neutralizing antibodies, a subset of antibodies that are specifically able to block the ability of the virus to enter a cel...

Read More

CYTODYN ANNOUNCES FIRST SITE IN THE SOUTHEASTERN USA TO ENROLL PATIENTS IN PHASE 2 CORONAVIRUS TRIAL

Proactive Investors | April 08, 2020

news image

The Novant Health network cares for around 5 million patients a year at nearly 700 locations, including 15 hospitals and hundreds of outpatient facilities and physician clinics. CytoDyn Inc (OTCQB:CYDY), the late stage biotech, said partner Novant Health has started enrolling patients in the company's Phase 2 randomized clinical trial using leronlimab for coronavirus (COVID-19) patients with mild-to-moderate symptoms. Novant Health is the second trial site in the USA and the first site in th...

Read More

RESEARCH SOLUTIONS ANNOUNCES PARTNERSHIP WITH BIO BUSINESS SOLUTIONS TO BRING ONE-CLICK SCIENTIFIC LITERATURE ACCESS TO THE BIOTECH INDUSTRY

Research Solutions | October 12, 2020

news image

Research Solutions/Reprints Desk (NASDAQ: RSSS), a pioneer in providing cloud-based workflow solutions for R&D driven organizations, today announced that it has partnered with BIO Business Solutions to help life sciences companies save time and money on scholarly literature access via its award-winning Article Galaxy research platform. Operated by the Biotechnology Innovation Organization (BIO), BIO Business Solutions is the industry's largest cost savings purchasing program. More than 4...

Read More

CELL AND GENE THERAPY

I-Mab | July 12, 2021

news image

THROUGH CUTTING-EDGE MRNA AND AI TECHNOLOGY PLATFORMS, I-MAB EXPANDS ITS EMERGING PORTFOLIO OF NEXT-GENERATION NOVEL ONCOLOGY THERAPEUTICS

I-Mab, a clinical-stage biopharmaceutical business dedicated to discovering, developing, and commercialization of novel biologics, announced today the signing of two new partnerships with Chinese emerging biotech firms to enhance its next-generation innovation pipeline. Collaborations with Immorna, an mRNA biotech company, and neoX Biotech, an AI-enabled R&D biotech company, provide I-Mab access to revolutionary technologies to search for new cancer treatments. I-Mab will crea...

Read More

GenScript | November 10, 2020

news image

GENSCRIPT RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR CPASS™ SARS-COV-2 NEUTRALIZATION ANTIBODY DETECTION KIT

GenScript USA Inc., the world's leading research reagent provider, announced today that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit. This is the first commercially available test to specifically detect neutralizing antibodies without the use of live virus. Neutralizing antibodies, a subset of antibodies that are specifically able to block the ability of the virus to enter a cel...

Read More

Proactive Investors | April 08, 2020

news image

CYTODYN ANNOUNCES FIRST SITE IN THE SOUTHEASTERN USA TO ENROLL PATIENTS IN PHASE 2 CORONAVIRUS TRIAL

The Novant Health network cares for around 5 million patients a year at nearly 700 locations, including 15 hospitals and hundreds of outpatient facilities and physician clinics. CytoDyn Inc (OTCQB:CYDY), the late stage biotech, said partner Novant Health has started enrolling patients in the company's Phase 2 randomized clinical trial using leronlimab for coronavirus (COVID-19) patients with mild-to-moderate symptoms. Novant Health is the second trial site in the USA and the first site in th...

Read More

Research Solutions | October 12, 2020

news image

RESEARCH SOLUTIONS ANNOUNCES PARTNERSHIP WITH BIO BUSINESS SOLUTIONS TO BRING ONE-CLICK SCIENTIFIC LITERATURE ACCESS TO THE BIOTECH INDUSTRY

Research Solutions/Reprints Desk (NASDAQ: RSSS), a pioneer in providing cloud-based workflow solutions for R&D driven organizations, today announced that it has partnered with BIO Business Solutions to help life sciences companies save time and money on scholarly literature access via its award-winning Article Galaxy research platform. Operated by the Biotechnology Innovation Organization (BIO), BIO Business Solutions is the industry's largest cost savings purchasing program. More than 4...

Read More